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1. Introduction 
Acute bronchitis is generally attributed to certain respiratory viruses, such as influenza 
virus A or B, respiratory syncytial virus, coronavirus, rhinoviruses, or others, although 
various bacteria have often been implicated in some cases, either as causative agents or as 
secondary agents following the initial virus infection (Gwaltney, 2002; Roxas & Jurenka, 
2007; See & Wark, 2008). Chronic bronchitis may also be exacerbated by the same agents. 
These viruses and bacteria initially encounter epithelial tissues of the nose, oral mucosa, 
bronchi and airway linings, which are composed primarily of epithelial cells covered by a 
“soup” of proteins, glycoproteins, muco-polysaccharides, some of which possess intrinsic 
antimicrobial properties (Diamond et al., 2008; Evans et al., 2010). Interspersed among these 
epithelial cells are occasional phagocytes and various types of leukocyte. The epithelial and 
other cells possess a variety of pattern recognition receptors (PRRs), on and within the cells, 
which serve as molecular sensors. In response to the recognition of a pathogen various 
signaling pathways may be activated, resulting in the production and/or secretion of many 
pro-inflammatory cytokines and chemokines, as well as antimicrobial peptides and other 
inflammatory mediators. Further signaling among resident cells of the tissues, and 
migrating leukocytes attracted to the site of invasion, causes amplification of the output of 
inflammatory molecules. This situation may become chronic and lead to prolonged 
bronchitis. However, recent virological studies have shown that direct cytopathic damage 
by the pathogen is not a prerequisite for the induction of inflammatory mediators. For 
example, rhinoviruses and respiratory syncytial virus generally show limited replication 
and cause little or no cellular damage, yet they can induce large amounts of inflammatory 
cytokines (Mosser et al., 2005; Sharma et al., 2009a).  
Thus, the epithelium has a two-fold function in response to potential pathogens; it has a 
barrier function and also serves as a sensor that signals an efficient antimicrobial response. 
This is the primary component of the innate “immune” or “non-specific” host response 
(Diamond et al., 2008; Evans et al., 2010). However, incomplete elimination of the pathogen, or 
over-stimulation of the responses, can lead to an excessive or chronic inflammatory condition. 
Since the pathogens comprise such a heterogeneous collection of causative agents, this 
presents a formidable obstacle to the design of therapeutic strategies, which have in the past 
focused on curbing the growth of a specific virus or bacterium (Fedson, 2009; Ludwig, 2009). 
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But because the majority of the symptoms may simply reflect this common non-specific host 
response to infecting agents, rather than to the cytopathic effects of the agents themselves, then 
a more rational therapeutic approach could be the application of antiinflammatory agents, 
especially if such agents also possess antimicrobial activities (Fedson, 2009).  
Many herbal extracts have been shown to contain antiviral and antimicrobial activities as 
well as antiinflammatory properties (Roxas & Jurenka, 2007; Vimalanathan & Hudson, 2009; 
Hudson, 2009; Burns et al., 2009). Consequently it seems worthwhile pursuing a multi-
functional approach, as a generic treatment for the symptoms of bronchitis and other 
pulmonary infections, especially if the agent can also control the spread and transmission of 
the pathogen. 
Among the more attractive candidates are extracts of certain species of Echinacea (Barnes et 
al., 2005; Hudson, 2009). However, a problem with commercial Echinacea extracts, and for 
that matter many other herbal formulations, is inadequate characterization and 
standardization. Consequently, different commercial sources derived from different species 
and plant parts may have variable chemical composition and hence variable or even 
insignificant bio-activities (Binns et al., 2002a; 2002b; Vohra et al., 2009). Recent studies in 
our laboratory have attempted to circumvent these limitations by focusing on chemically 
characterized and standardized preparations, some of which have been shown to possess 
potent antiviral activity, selective antibacterial activity and potent antiinflammatory activity, 
in human cell cultures and tissue models relevant to natural infections. 
2. Antiviral activities 
Earlier studies showed that only a few Echinacea extracts possessed significant antiviral activity 
(Binns et al., 2002; Table 1). E. purpurea aerial parts and roots contained potent anti-influenza 
virus and anti-HSV activities, which were distributed among more than one solvent fraction, 
probably reflecting the presence of more than one antiviral compound (Vimalanathan et al., 
2005; Hudson et al., 2005). However, there was no apparent correlation between antiviral 
activity and composition of the customary chemical markers (see section on Mechanisms). 
 
Echinacea sp. and 
plant part 
Susceptible viruses 
Anti-
inflammatory
references 
E. purpurea  
aerial parts 
Influenza viruses A & 
B; HSV-1; respiratory 
syncytial virus; 
rhinoviruses
+ 
Vimalanathan et al., 2005; Sharma 
et al, 2008a; Pleschka et al., 2009; 
Vimalanathan et al., 2009 
E. purpurea roots 
Influenza A, 
HSV-1
+ 
Hudson et al., 2005; Sharma et al., 
2008a; Vimalanathan et al., 2009 
E. angustifolia aerial 
parts 
Influenza A, 
HSV-1, rhinovirus
+ (weak) Vimalanathan et al., 2005, 2009  
E. angustifolia roots HSV-1 - Hudson et al., 2005
E. pallida, aerial 
parts & roots 
HSV-1/2 - Schneider et al., 2010 
E. sanguinea, 
inflorescence 
HSV-1, 
influenza A
nt Binns et al., 2002 
Other species Weak or no activity nt Binns et al., 2002
nt, not tested 
Table 1. Antiviral activities of Echinacea species.  
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In a more recent study, a series of aqueous and ethanol extracts of E. pallida aerial parts 
showed significant virucidal activity against HSV-1 and HSV-2 (Schneider et al., 2010) and 
some of the extracts also appeared to inhibit virus replication within infected cells. The 
different extracts had distinct chemical profiles, as expected, but the authors concluded that 
combinations of components, rather than individual compounds, were responsible for these 
different activities.  
Root extracts of three species were compared for antiviral activity in a similar manner to 
the aerial parts (Hudson et al., 2005). Aqueous extracts of E. purpurea roots contained 
relatively potent activity against influenza virus and HSV. In contrast, the antiviral 
activities of E. angustifolia roots were found in the ethanol and ethyl acetate fractions and 
included antirhinovirus activity, which was not detected in the aqueous fractions. E. 
pallida root extracts showed no antiviral activity whatsoever in any of the solvent 
fractions, in spite of the presence of the usual chemical markers for Echinacea species. 
Thus, in addition to the variation in activity among different species and extracts, there 
was no correlation between antiviral activity and relative content of caffeic acid 
derivatives, polysaccharides and alkylamides, suggesting that these compounds are not 
individually the active ingredients.  
Recent detailed studies with the standardized preparation Echinaforce (EF, comprising 
ethanol extracts of E. purpurea, 95% aerial parts plus 5% roots) revealed that this preparation 
was very active as a virucidal agent against several viruses with membranes, as indicated in 
Table 1. In addition to HSV-1 and respiratory syncytial virus, all tested human and avian 
strains of influenza A virus, as well as influenza B virus, were susceptible (Sharma et al., 
2009a; Pleschka et al., 2009). In addition, rhinoviruses were also equally susceptible at the 
relatively high concentrations of EF recommended for oral consumption (Table 1). Thus, EF 
at 1:10 dilution (equivalent to 1.6 mg/ml dry weight/volume) was capable of killing at least 
105 of all these infectious viruses by direct contact. In contrast, EF was found to be less 
effective intracellularly. Consequently, viruses already present within a cell could be 
refractory to the inhibitory effect of EF but virus particles shed into the extracellular fluids 
should be vulnerable. Therefore, the actions of Echinaforce should be manifest during initial 
contact with the virus, that is, at the inception of infection, and also during transmission of 
virus from infected cells.  
Additional experiments showed that continuous passage of influenza A virus in cell 
cultures in the presence of EF did not result in the emergence of resistant strains, whereas in 
contrast, passing the virus through successive cultures in the presence of Tamiflu rapidly 
produced Tamiflu-resistance (Pleschka et al., 2009). Furthermore, Tamiflu-resistant virus 
remained fully susceptible to EF. Therefore, continuous usage of Echinaforce in the 
population would be less likely to yield resistant strains of viruses than Tamiflu or other 
anti-influenza compounds currently in the market (Cheng et al., 2009). 
In mechanistic studies it was shown that EF, at concentrations recommended for oral 
consumption, was able to inhibit the influenza virus hemagglutinin and viral 
neuraminidase, both of which are necessary for influenza virus entry and dissemination 
(Pleschka et al., 2009; and unpublished observations). 
3. Antibacterial activities 
Upper respiratory infections (URI) are often accompanied by and may even enhance a 
significant bacterial infection, which may lead to more severe pulmonary infection and 
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bronchitis (Gwaltney, 2002; Roxas and Jurenka, 2007). Bacterial isolates from people with 
URI include normal naso-pharyngeal flora, such as Streptococcus pyogenes, a group A 
Streptococcus (GAS) responsible for pharyngitis or “strep throat”; Streptococcus pneumoniae; 
Staphylococcus aureus which may be highly antibiotic resistant, (e.g MRSA, methicillin-
resistant S.aureus), as well as Hemophilus influenzae and Legionella pneumophila, the agent of 
“Legionnaires disease”. In addition, Candida yeasts and bacterial opportunists are often 
present and may colonize respiratory tissues. Any of these organisms could lead to serious 
complications. 
 
Echinacea sp. and 
plant part 
Susceptible bacteria 
Anti-
inflammatory
references 
E. purpurea  
aerial parts 
S. pyogenes(G+);
H. influenzae(G-); 
L. pneumophila(G-) 
S. aureus (G+), weak 
M. smegmatis, weak
+ 
Sharma et al., 2008a;  
Vimalanathan et al., 2009 
E. purpurea roots L. pneumophila + 
Sharma et al., 2008a; 
Vimalanathan et al., 2009  
E. angustifolia roots 
S. pyogenes;
L. pneumophila 
- 
Sharma et al., 2008a; 
Vimalanathan et al., 2009  
Other species nt nt
G+, Gram-positive organisms; G-, Gram-negative organisms; nt, not tested 
Table 2. Antibacterial activities of Echinacea species 
Studies with various commercial Echinacea preparations indicated a wide variety of responses 
by different human pathogenic bacteria (Sharma et al., 2008a). Among the respiratory bacteria 
tested, three of them, S. pyogenes, H. influenza and L. pneumophila, were very sensitive to one or 
more of the extracts, particularly ethanol extracts (Table 2). Two others, S. aureus and 
Mycobacterium smegmatis, were slightly sensitive to some extracts while other bacteria tested 
were essentially resistant. Since the composition of the extracts varied considerably with 
respect to caffeic acids, alkylamides and polysaccharides, it was not possible to relate any of 
these to antibacterial activity. Furthermore, the distinct patterns of activity suggested that there 
was no common mechanism of antibacterial activity. Since Echinacea is a member of the 
Asteraceae family, which is known to contain many plants rich in antibacterial polyynes and 
thiophenes (Hudson & Towers, 1999), such compounds might also have contributed to the 
activities observed. This selective antibacterial activity should be considered an advantage, 
since it suggests that only certain organisms associated with pulmonary infections would be 
killed or controlled, while other normal flora might be spared. 
4. Antiinflammatory activity 
In some cases, the inflammatory responses due to proinflammatory cytokines, chemokines 
and other mediators (eicosanoids, kinins, nitric oxide), may be excessive or chronic, and 
consequently a dampening down or suppression could be beneficial. Many extracts derived 
from medicinal plants have been shown to possess anti-inflammatory activities, at non-toxic 
concentrations, in a variety of animal and cellular models, although these have not usually 
involved infectious agents (Burns et al., 2009). 
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Studies on rhinovirus infected human bronchial and lung epithelial cell lines showed that 
the virus could stimulate the secretion of more than 30 different cytokines, including the 
proinflammatory IL-1, IL-6, IL-8, and TNF, which are known to be collectively involved in 
many of the symptoms common to colds and ‘flu. However, certain Echinacea preparations 
were able to completely or partly reverse this stimulation (Sharma et al., 2008a). In some 
cases, these stimulations and inhibitions were a reflection of corresponding alterations in 
specific gene transcription, but this was not always the case, indicating that transcriptional 
changes and secretion of mature cytokine proteins were not necessarily linked (Altamirano-
Dimas et al., 2007; 2009).  
More recent studies by Sharma and colleagues focused on the application of standardized E. 
purpurea extract (Echinaforce) to epithelial cells and tissues infected by viruses or bacteria. In 
rhinovirus infected human bronchial and lung epithelial cell lines, the virus stimulated the 
secretion of numerous cytokines, including the proinflammatory IL-1, IL-6, IL-8 and TNF, 
which are known to be collectively involved in many of the symptoms common to 
pulmonary infections. Echinaforce was able to completely or partly reverse this stimulation 
(Sharma et al., 2008b; 2009a). It was also shown that EF could be added before or after virus 
infection, with similar success, and furthermore the results were not affected by virus dose 
or time of exposure to EF (Sharma et al., 2008b). 
 
cytokine RV flu RSV Ad 3 S.pyog S.aureus L.pneum H.infl 
IL-1a + + + +     
IL-4     + +   
IL-5    +     
IL-6 + + + + + + + + 
IL8 
(CXCL-8) 
+ + + + + + + + 
TNF + + + +     
GRO + + +  + +   
VEGF      +   
CCL-3   + + + +   
CCL-4   + +     
CCL-5   +      
MCP-1     + +   
RV, rhinovirus; flu, influenza virus; RSV, respiratory syncytial virus; Ad 3, adenovirus type 3; S.pyog, 
Streptococcus pyogenes; S.aureus, Staphylococcus aureus; L.pneum, Legionella pneumophila; H.infl, 
Hemophilus influenzae. 
Table 3. Cytokines/chemokines induced by viruses/bacteria and reversed by EF 
A similar result was obtained with other viruses and cell types. Thus HSV-1, influenza A 
virus, adenovirus type 3 and 11, and respiratory syncytial virus, all stimulated the secretion 
of proinflammatory cytokines, although the pattern and relative amounts of stimulation 
differed; but in each case the stimulation was reversed by EF (Sharma et al., 2009a; Table 3). 
However, only live infectious viruses were able to do this, for infection by equivalent doses 
of ultraviolet-inactivated viruses failed to elicit the responses. This suggests that the virus 
has to enter the cells and undergo some degree of gene expression in order to stimulate the 
cytokine expression and secretion. It is also interesting that adenoviruses, which are not 
www.intechopen.com
 
Approaches to Bronchitis 
 
48
vulnerable to direct attack by Echinacea, could nevertheless stimulate cytokine secretion, and 
were susceptible to cytokine inhibition (Sharma et al., 2009a). 
In an attempt to correlate immune modulation effects with specific classes of Echinacea 
components, various solvent-fractionated extracts, derived from three species of Echinacea, 
were evaluated for their possible inhibitory effects on the secretion of proinflammatory 
cytokines IL-6 and IL-8 by human bronchial epithelial cells infected with rhinovirus type 14. 
All of the E. purpurea fractions, comprising aqueous or ethanol extracts of roots, leaves and 
stems, but to a lesser degree flowers, strongly inhibited the secretion of both cytokines. In 
contrast, corresponding fractions derived from E. angustifolia and E. pallida showed 
relatively weak cytokine-inhibitory activity, and their aqueous fractions significantly 
enhanced cytokine secretion, both in virus-infected and in uninfected cells (Vimalanathan et 
al., 2009). These properties did not correlate with the presence or absence of chemical 
markers referred to above. 
Several human pathogenic bacteria, including S. pyogenes, S. aureus, H. influenzae, L. 
pneumophila and M. smegmatis, also stimulated the secretion of IL-6, IL-8, as well as other 
cytokines in cell cultures but in all these cases, the stimulation was reversed by EF, even for 
those bacteria that were relatively resistant to the bactericidal effect of EF, such as S. aureus 
(Sharma et al., 2010; Table 3). Thus, Echinaforce evidently reversed the stimulation of 
proinflammatory cytokines regardless of the inducing bacterium or virus. This indicates that 
EF is effectively a general anti-inflammatory agent and should be capable of ameliorating 
many of the symptoms of URI. 
5. Mucin secretion 
The secretion of excessive mucus is a common feature of bronchitis, and accordingly many 
pharmaceuticals have been designed to relieve this symptom, usually with the 
accompaniment of undesirable side effects.  
In our studies, rhinoviruses induced the secretion of excess MUC5A, the dominant 
respiratory mucin, in bronchial epithelial cells in culture and in cultured airway tissues, and 
EF reversed this secretion in both systems (Sharma et al., 2009b, Table 4), suggesting that 
this could be an additional benefit of Echinacea treatment. This result was supported by 
histochemical examination of cultured airway tissues, which revealed the conspicuous 
presence of mucopolysaccharide-filled goblet cells in virus-infected tissues, and their 
relative scarcity in EF treated tissues, which appeared normal (Sharma et al., 2009b). 
 
Treatment In cells (ratio) In tissue (ratio) 
None-control 1.00 1.00 
Echinacea (EF) only 0.76 0.82 
Virus only (RV) 2.18 2.00 
Echinacea (EF) + RV 0.64 0.76 
Table 4. Mucin (MUC 5A) secretion in cells (BEAS-2B) and tissues 
6. 3-D tissues of human airway epithelium 
It is important that the cell culture models used to evaluate anti-infectious agents reflect 
conditions in vivo as far as possible (Nickerson et al., 2007). This condition was evaluated 
by means of a commercial source of normal human airway epithelial tissue (EpiAirwayTM 
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tissue, a 3-D organotypic model), which could be propagated in vitro under defined 
conditions such that tissue architecture and differentiation patterns were preserved. The 
objective was to assess the effects of rhinovirus infection, and EF, on various parameters 
of tissue integrity and cytokine induction (Sharma et al., 2009b). Individual replicate 
tissue samples, maintained as inserts in culture for three days or three weeks, were 
infected with rhinovirus type 1A (RV1A), EF alone, a combination of the two, or medium 
only. None of the treatments affected the histological appearance or integrity of the 
tissues, all of which maintained a high level of cell viability and preservation of cilia, with 
the exception of the virus-induced muco-polysaccharide inclusions in the goblet cells (as 
mentioned above). There was no evidence of virus replication, although the RV infected 
tissues secreted substantial amounts of the proinflammatory cytokines IL-6 and IL-8, and 
this response was reversed by EF treatment. These results confirmed the previous 
findings derived from studies of bronchial and lung epithelial cell lines (above), namely, 
that RV infection resulted in a substantial inflammatory response in the absence of virus 
replication. In a preliminary study, similar results were obtained for influenza virus-
infected tissues.  
7. Mechanisms of action 
The results described have indicated that some Echinacea extracts evidently contain 
compounds, or combinations of compounds, with the ability to interact specifically with 
viral and bacterial targets (Pleschka et al., 2009; Hudson, 2009; Schneider et al., 2010; Sharma 
et al., 2010). In addition, these extracts can affect various signaling pathways of epithelial 
cells and inhibit the virus/bacterium-induced secretion of cytokines/chemokines and other 
inflammatory mediators that were responsible for the pulmonary symptoms. Since many 
signaling pathways can be affected by Echinacea in different cell types (Altamirano-Dimas et 
al., 2007; 2009; Wang et al., 2008), it is conceivable that the overall beneficial effects are due 
to a particular combination of compounds acting synergistically. Examples of synergism in 
herbal medicine have been described and in some cases validated experimentally (Spelman, 
2006; Burns et al., 2009) and it is likely that certain Echinacea preparations also display 
synergism. However, in spite of our attempts to correlate bioactivities of Echinacea 
preparations with recognized chemical markers, ie. polysaccharides, caffeic acid derivatives, 
and alkylamides (Binns et al., 2002; Barnes et al., 2005), we have not succeeded in doing so. 
In contrast, preliminary evidence in our laboratory has implicated other classes of 
compounds (unpublished data).  
8. Relevance of bioactivities to normal consumption 
Echinacea extracts intended for treatment of colds and flu, and sore throats, are normally 
marketed in the form of tinctures, sprays, lozenges, etc. for oral consumption. The active 
ingredients therefore acquire immediate exposure to the mucosal epithelia. According to our 
studies with standardized preparations (as described above), the recommended applications 
ensure that physiologically relevant amounts, that is to say, adequate local antiviral, 
antibacterial and antiinflammatory concentrations, are achieved under normal conditions of 
consumption. Subsequent absorption and metabolism of the various components, however, 
are less relevant to this discussion, since the sites of infection and inflammation are at the 
level of airway epithelial tissues. 
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9. Conclusions 
These studies on Echinacea, especially the standardised formulations such as Echinaforce, 
indicate multiple actions of the herbal preparation, resulting either from the individual 
activities of several compounds, or the synergistic effect of different compounds. The 
resulting benefits are: (i) direct virucidal activity/activities against several viruses involved 
in colds, ‘flu and bronchitis, at concentrations which are not cytotoxic; (ii) direct bactericidal 
actions against certain potentially pathogenic respiratory bacteria; (iii) reversal of the 
proinflammatory response of epithelial cells and tissues to various viruses and bacteria; (iv) 
reversal of the excessive mucin secretion induced by virus. Thus, a combination of these 
beneficial activities could reduce the amount of prevailing viable virus and bacteria, and 
their transmission, and also lead to amelioration of the symptoms of bronchitis.  
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